Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery

9 agosto 2013 aggiornato da: Imperial College London

A Neoadjuvant Study of Chemotherapy Versus Endocrine Therapy in Postmenopausal Patients With Primary Breast Cancer

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. It is not yet known whether giving more than one drug (combination chemotherapy) or giving letrozole before surgery is more effective in treating women with breast cancer.

PURPOSE: This randomized phase III trial is studying giving combination chemotherapy before surgery to see how well it works compared with letrozole given before surgery in treating postmenopausal women with breast cancer that can be removed by surgery.

Panoramica dello studio

Descrizione dettagliata

OBJECTIVES:

  • To compare the efficacy and tolerability of cytotoxic chemotherapy versus aromatase inhibition for the down-staging of strongly ER+ primary breast cancer in postmenopausal women.
  • To identify biological predictors of response to these two treatment modalities.

OUTLINE: This is a multicenter pilot, feasibility study followed by a randomized study. In the pilot study, a record of all patients screened and invited to participate in the study is compiled. Reasons for failure to recruit will be recorded. Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients who do not achieve at least partial response after 3 courses receive docetaxel IV on day 1 of 3-week courses for an additional 3 courses.
  • Arm II: Patients receive oral letrozole daily for 18-23 weeks until day of surgery.

Patients in both arms undergo surgery at week 18-23. Most patients then receive adjuvant therapy.

Quality of life is assessed at baseline, periodically during study treatment, and then during follow up.

Blood is collected pre-treatment, at mid-treatment, and before surgery. Blood is then collected every 6 months for 2 years. Blood samples and preserved tumor samples are used for correlative studies.

After completion of surgery, patients are followed up at least annually for 10 years.

PROJECTED ACCRUAL: A total of 40 patients for the pilot study and 716 patients for the phase III study will be accrued.

Tipo di studio

Interventistico

Iscrizione (Anticipato)

756

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Seoul, Corea, Repubblica di, 138-736
        • Asan Medical Center - University of Ulsan College of Medicine
    • England
      • Isleworth, England, Regno Unito, TW7 6AF
        • West Middlesex University Hospital
      • London, England, Regno Unito, W6 8RF
        • Charing Cross Hospital
      • London, England, Regno Unito, W2 1NY
        • St. Mary's Hospital
      • London, England, Regno Unito, SE1 9RT
        • Guy's Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 70 anni (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

DISEASE CHARACTERISTICS:

  • Histologically proven primary invasive breast cancer that is thought to be suitable for neoadjuvant treatment

    • No cytological proof of malignancy only
    • T2 tumor or greater (≥ 20 mm by ultrasound) or any T stage with nodal disease ≥ 20 mm diameter on ultrasound assessment
    • No evidence of distant metastatic disease as disclosed by bone scan, liver, and chest imaging
  • Definite indication for neoadjuvant and adjuvant chemotherapy
  • Primary tumor amenable to biopsy
  • No inoperable disease that is judged very unlikely to be rendered operable by neoadjuvant treatment
  • No inflammatory breast cancer
  • No bilateral invasive breast cancer
  • HER-2 positivity is NOT an exclusion criterion in the feasibility (pilot) study
  • Estrogen receptor (ER) positive tumor

    • No ER-poor disease as defined locally (e.g., H-score < 100, Allred 3/4/5)
    • Allred 6/7/8, H-score H ≥100 allowed

PATIENT CHARACTERISTICS:

  • Postmenopausal, meeting 1 of the following criteria:

    • Over 12 months since last menstrual period
    • Postmenopausal gonadotrophin levels (luteinizing hormone or follicle-stimulating hormone levels above local criteria)
    • Postmenopausal estradiol levels below local criteria
    • Prior bilateral oophorectomy
    • Menopause induced by gonadotrophin-releasing hormone not allowed
  • WHO performance status 0 or 1
  • WBC ≥ 3.0 × 10^9/L
  • ANC ≥ 1.5 × 10^9/L
  • Platelets ≥ 100 × 10^9/L
  • Hemoglobin > 9 g/dL
  • AST/ALT ≤ 1.5 times upper limit of normal (ULN)
  • Serum bilirubin ≤ 1.5 times ULN
  • Alkaline phosphatase ≤ 1.5 times ULN
  • Serum creatinine ≤ 1.5 times ULN
  • No active, uncontrolled infection
  • No malignancy within the past 10 years except for basal cell carcinoma or cervical carcinoma in situ

    • Treatment for previous malignancy confined to resection alone
  • No concomitant medical, psychiatric, or geographic problems that might prevent completion of treatment or follow-up
  • No known severe hypersensitivity to aromatase inhibitors
  • No contraindication to receiving aromatase inhibitors (clinical evidence or recorded history of osteoporosis)
  • No other serious illness or medical condition including any of the following:

    • Congestive heart failure or unstable angina pectoris
    • Myocardial infarction within the past year
    • Uncontrolled hypertension or high-risk uncontrolled arrhythmias
    • History of significant neurologic or psychiatric disorders, including psychotic disorders, dementia, or seizures, that would prohibit the understanding and giving of informed consent
    • Active peptic ulcer
    • Unstable diabetes mellitus
  • No definite contraindications for the use of corticosteroids
  • No contraindication to receiving combination anthracycline/taxane chemotherapy
  • Willing to undergo repeat biopsies

PRIOR CONCURRENT THERAPY:

  • No hormone replacement therapy within 4 weeks of starting treatment
  • No chronic oral treatment with corticosteroids unless initiated > 6 months prior to study entry and at low dose (≤ 20 mg methylprednisolone or equivalent)
  • No concurrent warfarin or heparin therapy

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm I
Patients receive fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
Dato IV
Dato IV
Dato IV
Dato IV
Sperimentale: Arm II
Patients receive oral letrozole daily for 18-23 weeks until day of surgery.
Dato oralmente

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Feasibility of patient recruitment (pilot)
Feasibility of tissue collection (pilot)
Ultrasound (or mammogram) response rate

Misure di risultato secondarie

Misura del risultato
Sopravvivenza globale
Qualità della vita
Sopravvivenza libera da malattia
Tasso di risposta clinica
Radiologic response rate by ultrasound (pilot)
Pathological complete response rate (pCR) defined as no residual invasive or pre-invasive carcinoma in breast or axilla (pilot)
Plasma DNA changes in relation to treatment response
Rate of conservation surgery
Degree of pathological response
Ki-67 changes and its relationship to treatment response
Length of time to maximum response within the treatment period
Tolerability of the various treatments
MRI response

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio

1 settembre 2008

Completamento primario (Effettivo)

1 marzo 2010

Completamento dello studio (Effettivo)

1 marzo 2011

Date di iscrizione allo studio

Primo inviato

20 agosto 2009

Primo inviato che soddisfa i criteri di controllo qualità

20 agosto 2009

Primo Inserito (Stima)

21 agosto 2009

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Stima)

12 agosto 2013

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 agosto 2013

Ultimo verificato

1 agosto 2011

Maggiori informazioni

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi